PRESS RELEASES

Year
October 30 | 2019
RAPT Therapeutics Announces Pricing of Initial Public Offering
October 23 | 2019
RAPT Therapeutics Announces Initiation of First-in-Human Phase 1 Study of RPT193
October 22 | 2019
RAPT Therapeutics Strengthens Board with Addition of Veteran Biotechnology Executive Wendye Robbins, M.D.
July 08 | 2019
RAPT Therapeutics Announces the Appointment of Emma Guttman-Yassky, M.D., Ph.D., a Leading Expert in the Field of Inflammatory Skin Diseases, to its Scientific Advisory Board
July 08 | 2019
RAPT Therapeutics Announces Promotion of Key Research and Development Senior Leaders
June 18 | 2019
RAPT Therapeutics Completes $37 Million Series C Extension
May 24 | 2019
FLX Bio Announces Name Change to RAPT Therapeutics
May 20 | 2019
Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study
May 13 | 2019
FLX Bio Highlights Preclinical Atopic Dermatitis and Asthma Data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
March 05 | 2019
FLX Bio to Present at Cowen and Company 39th Annual Health Care Conference